Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
Want to see ACTU full AI Analyst Report?
ACTU Stock Chart & Stats
$2.31
-$0.11(-1.36%)
At close: 4:00 PM EST
$2.31
-$0.11(-1.36%)
Day’s Range― - ―
52-Week Range$1.58 - $11.99
Previous CloseN/A
Volume10.16K
Average Volume (3M)117.56K
Market Cap
$71.13M
Enterprise Value$58.38M
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)$404.99K
Price to Earnings (P/E)―
Beta1.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding23,709,944
10 Day Avg. Volume189,225
30 Day Avg. Volume117,563
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)16.24
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.61
Forecast
1Y Price Target
$15.00Price Target Upside549.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pediatric DevelopmentObserved complete responses in pediatric patients with Ewing sarcoma and neuroblastoma support planned pediatric Phase 2 development and may qualify the program for regulatory incentives if replicated.
Phase 2 EfficacyA randomized Phase 2 study showed a statistically significant improvement in overall survival versus standard chemotherapy, providing a strong signal to support a confirmatory pivotal trial.
Regulatory PathwayEngagement with the European Medicines Agency about a Conditional Marketing Authorization pathway could enable earlier market access and create options for non-dilutive funding or strategic partnerships.
Bears Say
Clinical Trial ExecutionNotable hematologic toxicity could complicate trial design and enrollment, increasing the complexity and cost of conducting a pivotal study.
Hematologic SafetyHigher rates of severe neutropenia in the elraglusib arm raise safety concerns that could limit tolerability and require treatment modifications.
Regulatory Support RiskRegulators' refusal to grant expedited designation indicates a need to demonstrate a clear and substantial improvement over current therapies before accelerated pathways will be available.
Actuate Therapeutics, Inc. News
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $1.58 and its highest was $11.99 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Actuate Therapeutics, Inc.’s market cap is $71.13M.
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 23,709,944 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actuate Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (549.35% Upside)
$15.00 (549.35% Upside)
Blogger Sentiment
Bullish
ACTU Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 24.0%
Last 30 Days ▲ 24.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.12%
12-Months-Change
Fundamentals
Return on Equity
-799.65%
Trailing 12-Months
Asset Growth
50.62%
Trailing 12-Months
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
ACTU Stock 12 Month Forecast
Average Price Target
$15.00
▲(549.35% Upside)
Technical Analysis
Agenus
―
Black Diamond Therapeutics
―
Nkarta
―
C4 Therapeutics
―
Kyverna Therapeutics, Inc.
―